24 completed, 9 recruiting, 9 unknown, 7 terminated. 17 Phase 2, 16 Phase 1, 11 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow All: new trials by email Literature Review of All trials Research Report on All
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort All Conditions, All | Enrolling by invitation | Head Diagnostics | 120 | 2026-09-28 | 2026-10-05 | |
| my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults my.naviGATE Digital Tool - Sarcoma, Osteosarcoma | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 143 | 2026-08-20 | 2026-04-08 |
| A Multicenter Study of CAR-T Cells in Primary Ph+All CD19 CAR-T cells - ALL | Phase 2 | Recruiting | Zhejiang University | 50 | 2025-11-30 | 2025-12-04 |
| A Long Term Follow-up Study of TScan TCR-T Products Observational - AML, ALL | Recruiting | TScan Therapeutics, Inc. | 1000 | 2025-09-09 | 2025-09-10 | |
| UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy Infusion of CD34 selected hematopoietic stem cells - AML, ALL | Phase 1 | Recruiting | University of Alabama at Birmingham | 50 | 2025-04-22 | 2026-04-13 |
| Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults KSM-66 Ashwagandha Root Extract - All | Completed | SF Research Institute, Inc. | 200 | 2024-02-15 | 2025-11-06 | |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. - Hematologic Malignancy, Leukemia | Recruiting | Children's Hospital Medical Center, Cincinnati | 30 | 2023-11-15 | 2026-10-01 | |
| Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer Transcranial photobiomodulation (tPBM) - Mobile System - ALL, Hodgkin Lymphoma | Not applicable | Completed | St. Jude Children's Research Hospital | 44 | 2023-01-05 | 2026-10-02 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| commd7 Gene Expression in ALL Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). - ALL | Unknown | Assiut University | 102 | 2022-11-01 | 2022-10-24 | |
| Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL Inotuzumab Ozogamicin - ALL, MRD-positive | Phase 2 | Recruiting | Sheng-Li Xue, MD | 42 | 2022-08-01 | 2025-11-21 |
| Patient Satisfaction in the Orthopedic Surgery Clinic Review - All | Not applicable | Withdrawn | NYU Langone Health | 2022-08-01 | 2022-12-06 | |
| Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy Cardiac MRI - DLBCL, Multiple Myeloma | Unknown | University Hospital, Bonn | 60 | 2022-05-16 | 2022-06-15 | |
| Venetoclax Plus Inotuzumab for B-ALL Venetoclax, Dexamethasone, Inotuzumab Ozogamicin - B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 23 | 2021-09-24 | 2026-01-29 |
| ACL Reconstruction With/Without ALL Reconstruction ACL reconstruction, ALL anatomic, ALL tenodesis - ACL Injury, ALL | Not applicable | Unknown | Centre of Postgraduate Medical Education | 762 | 2021-09-01 | 2022-07-18 |
| Optical Genome Mapping in Hematological Malignancies MDS, ALL | Unknown | University Hospital, Brest | 200 | 2021-09-01 | 2021-08-17 | |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Clofarabine, Fludarabine, Busulfan - AML, ALL | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2020-11-20 | 2026-03-13 |
| GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084 - B-precursor Acute Lymphoblastic Leukemia, ALL | Phase 1 / Phase 2 | Terminated | AO GENERIUM | 14 | 2020-10-15 | 2026-09-21 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| Risk of Osteoarthritis of the Knee at Least 5 Years After ACL Reconstruction: Comparative Study Between an Isolated ACL Reconstruction and a Reconstruction Combining ACL and ALL Radiography - ACL, Anterior Curciate Ligament | Not applicable | Unknown | GCS Ramsay Santé pour l'Enseignement et la Recherche | 180 | 2020-04-15 | 2021-11-17 |
Showing 20 of 54. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Hodgkin Disease (13) · Leukemia, Myeloid, Acute (10) · Lymphoma, Non-Hodgkin (9) · Leukemia (8) · Myelodysplastic Syndromes (7) · Myeloproliferative Disorders (7) · Lymphoma (6) · Multiple Myeloma (6) · Hematologic Neoplasms (5) · Burkitt Lymphoma (4) · Leukemia, Biphenotypic, Acute (4) · Lymphoma, B-Cell (4) · Neoplasms (4) · Anemia, Refractory, with Excess of Blasts (3)
Hemic and Lymphatic Diseases (38) · Neoplasms by Histologic Type (37) · Immune System Diseases (35) · Neoplasms (35) · Immunoproliferative Disorders (34) · Lymphoproliferative Disorders (34) · Hematologic Diseases (33) · Lymphatic Diseases (33) · Leukemia (21) · Leukemia, Lymphoid (21) · Lymphoma (15) · Bone Marrow Diseases (14) · Leukemia, Myeloid (12) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (10)
fludarabine (6) · Cyclophosphamide (5) · Cytarabine (4) · Dexamethasone (4) · Methotrexate (4) · fludarabine phosphate (4) · Busulfan (3) · Calcium Dobesilate (3) · Mycophenolic Acid (3) · Vincristine (3) · Clofarabine (2) · Cyclosporine (2) · Etoposide (2) · Inotuzumab Ozogamicin (2) · Mercaptopurine (2)
Dana-Farber Cancer Institute (3) · National Cancer Institute (NCI) (3) · Beth Israel Deaconess Medical Center (2) · Duke University (2) · AO GENERIUM (1) · Abramson Cancer Center at Penn Medicine (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Assiut University (1) · Baseline Study LLC (1) · Baylor College of Medicine (1) · Boston Children's Hospital (1) · Boston Medical Center (1) · Boston University (1) · Centre of Postgraduate Medical Education (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (35) · France (3) · China (2) · Germany (2) · Australia (1) · Belgium (1) · Canada (1) · Poland (1) · Russia (1) · Singapore (1) · South Korea (1) · Spain (1) · Sweden (1)
David E Avigan, MD (2) · David F McDermott, MD (2) · Nirali N Shah, M.D. (2) · Todd Cooper, DO (2) · Adam Lamble, MD (1) · Amy Walz, MD (1) · Andrew Rokito, MD (1) · Annkristin Heine, MD (1) · Brian Jack, MD (1) · Brigitta Omazic, PhD (1) · David Porter, MD (1) · Dmitrij Kravchenko, MD (1) · Dolores Grosso, DNP, CRNP (1) · Dong Hwan Kim (1) · Elizabeth Hexner, MD (1)
PMID 34687939, PMID 37486616, PMID 19189907, PMID 20577971, PMID 22514241, PMID 24047754, PMID 24573552, PMID 24951467, PMID 25319501, PMID 25852054, PMID 26858124, PMID 31310353, PMID 32286905, PMID 32883871, PMID 33413596, PMID 33764809, PMID 34309174, PMID 34983769, PMID 35148417, PMID 35622074, PMID 35675590, PMID 35850765, PMID 35872137, PMID 37039013, PMID 37154412, PMID 37295816, PMID 37632535, PMID 38376944, PMID 38969081, PMID 39081837, PMID 39606360, PMID 39705694, PMID 39801490, PMID 40630050, PMID 41063394, PMID 41411486, PMID 41671463, PMID 42789493
2015 (1), P01CA049605 (1)